Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Razelle Kurzrock(Medical College of Wisconsin), Rashmi Chugh(University of Michigan), Adrienne I. Victor(University of Rochester), Elad Sharon(National Cancer Institute), Megan Othus(Cancer Research And Biostatistics), G. Thomas Budd(Cleveland Clinic), Mark Agulnik(Northwestern University), Kirsten Leu(Nebraska Methodist College), Charles D. Blanke(Oregon Health & Science University), Melissa Plets(Cancer Research And Biostatistics), Chung-Tsen Hsueh(Loma Linda University), Sandip Pravin Patel(University of San Diego), Suresh Nair(Lehigh Valley Hospital-Pocono), Young Kwang Chae(Johns Hopkins University), Chris Ryan(University of Portland), Howard Streicher(National Cancer Institute), Benjamin Powers(University of Kansas Medical Center), Edward Mayerson(Cancer Research And Biostatistics), Ashish Sangal(Goodyear (United States))
Cited by 159
Related Papers
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009
|New England Journal of Medicine|2009|1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k